Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception

Phase 3 Completed 2000 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedSingle-groupOpen-label

Summary

To evaluate the safety and contraceptive efficacy of an oral contraceptive containing a combination of LNG 90 mg/EE 20 mg in a continuous-use regimen.

Timeline

Start: 2003-02
Primary completion: 2005-10
Completion: 2005-10

Publications

Reid RL, Fortier MP, Smith L, Mirkin S, Grubb GS, Constantine GD. Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada. Contraception. 2010 Dec;82(6):497-502. doi: 10.1016/j.contraception.2010.06.002. Epub 2010 Jul 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Levonorgestrel	Small molecule	90 mg	—
Subject	ethinyl estradiol	Small molecule	20 mg	—

Indications

No indication recorded.